Literature DB >> 7237467

Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.

H Y Yap, G R Blumenschein, F Schell, G P Bodey.   

Abstract

Twenty-nine patients with metastatic breast cancer were treated with methyl-GAG at an initial starting dose of 500 mg/m2 iv weekly and then escalated by 50 mg/m2/week to tolerance. There were two partial responders among the 26 evaluable patients. Gastrointestinal and cutaneous reactions were the limiting toxic effects of methyl-GAG. Myelosuppression was mild and infrequent.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7237467

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

1.  Phase II evaluation of MGBG in non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Authors:  R B Vance; W A Knight; T T Chen; J J Costanzi; A F LoBuglio
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group.

Authors:  W A Knight; R M O'Bryan; B Samal; J J Costanzi
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 3.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

4.  Irreversible inhibition of putrescine-stimulated S-adenosyl-L-methionine decarboxylase by berenil and pentamidine.

Authors:  E Karvonen; L Kauppinen; T Partanen; H Pösö
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.